Table 2.
Number of tuberculosis episodes and time to tuberculosis disease, by individual biologic therapy
| Biologic therapies | Total no of patients treateda | No of TB episodes b (% of TB episodes/ total treated) c | Time to TB (months) d Median (IQR) | |
|---|---|---|---|---|
| All biologics | – | 41 | 8.30 (3.67–27.70) | |
| TNF-α inhibitors | 209 | 20 | 18.95 (5.08–32.79) | |
| adalimumab | 48 | 4 (8.3%) | 12.56 (3.20–18.90) | |
| etanercept | 49 | 3 (6.1%) | 33.84 (12.59–46.82) | |
| golimumab | 12 | 2 (16.7%) | 4.82 (4.33–5.31) | |
| infliximab | 100 | 11 (11.0%) | 27.70 (3.64–39.02) | |
| Non-TNF-α inhibitors | 441 | 21 | 7.43 (2.83–16.24) | |
| abatacept | 4 | 0 | – | |
| rituximab | 418 | 20 (4.8%) | 7.08 (2.48–18.02) | |
| tocilizumab | 18 | 1 (5.6%) | 15.02 (15.02–15.02) | |
| ustekinumab | 1 | 0 | – | |
atotal number of patients exposed to a biologic therapy at any point in study period (one patient may be exposed to multiple biologic therapies)
bnumber of tuberculosis episodes (single or multiple) per patient according to the most recent biologic therapy used before or at the time of tuberculosis disease diagnosis (n = 41).
cpercentage of tuberculosis disease episodes (based on most recent biologic therapy used) per total number of patients exposed to a biologic therapy.
dtime to tuberculosis disease in months from the start of the most recent or current biologic used to the date of tuberculosis disease diagnosis.
TB tuberculosis, TNF-α tumour necrosis factor-alpha, min minimum, max maximum, IQR interquartile range